Q1 2026 Operating Profit Surges 1,025% YoY, Sales Up 27.7%

Preliminary consolidated results: Sales 66.96 billion KRW (+27.7% YoY), Operating profit 11.53 billion KRW (+1,024.6% YoY), Net income 15.20 billion KRW (+2,044.8% YoY)
Compared to the previous quarter (Q4 2025), sales declined 48.1% and operating profit 56.1%, due to a high base effect
Pre-tax income 17.67 billion KRW (+1,032.4% YoY), Net income attributable to controlling 15.06 billion KRW (+1,343.2% YoY)
These figures are preliminary and unaudited, subject to change
IR presentation scheduled for April 27, 2026

Filing: Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
Company: ST PHARM (237690)
Submission: ST PHARM CO., LTD.
Receipt: 04-27-2026
Under KRX KOSDAQ Market Division